Search

Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team and the ECOG-ACRIN Cancer Research Group, have found that abbreviated breast magnetic resonance imaging (MRI) detected more cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breast tissue.

… Tuesday, February 25, 2020 Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team and the ECOG-ACRIN Cancer Research Group , have found that abbreviated breast magnetic resonance imaging (MRI) detected more cancers than digital breast tomosynthesis

… Tuesday, June 25, 2024 The internet is full of “miracle cures” for cancer and alleged surefire ways to prevent it, and well-meaning people may urge cancer patients to just try them out in hopes of eliminating their disease. Some patients, worried that conventional treatments won’t work or pose significant

Practical tips for caregivers helping an older relative or friend make decisions about cancer treatment.

… Friday, November 25, 2016 Summary An older adult who is diagnosed with cancer may need help making treatment decisions. Our Geriatrics Service Chief discusses how to lend support. Highlights Decisions should be made based on each individual’s unique situation. It’s important to consider the goals of

A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.

… Friday, June 9, 2017 Two years ago at the annual meeting of the American Society of Clinical Oncology, researchers from Johns Hopkins wowed an audience with results from a recent immunotherapy clinical trial. People with a type of colorectal cancer that bore a genetic abnormality called mismatch repair

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

… Wednesday, May 18, 2022 DNA sequencing tests that look for mutations in cancer-associated genes have become the standard of care at leading centers, including at Memorial Sloan Kettering Cancer Center (MSK). MSK’s test, called MSK-IMPACT™, can detect mutations in 500-plus cancer-related genes. This information

For the first time, scientists have shown that the gene APC, which is mutated in the vast majority of colorectal cancers, might be a promising target for future therapies.

… Wednesday, July 1, 2015 Summary Working in mice, Memorial Sloan Kettering scientists have found that genetic alterations in the APC gene, which are found in more than 90 percent of colorectal cancers, play an important role in driving the disease. The researchers are now asking whether potential drugs

Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic approaches for improving patient outcomes.

… Tuesday, December 26, 2023 Physicians and researchers at  MSK Kids , Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic

In 1971, Richard Nixon launched a “war on cancer.” It’s still raging.

… Wednesday, January 1, 2020 In 2016, when Vice President Joseph Biden announced the “Cancer Moonshot” initiative , many in the scientific world felt a twinge of déjà vu. This wasn’t the first time that officials in the US government had set their sights on an ambitious plan to conquer cancer. In fact,

New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.

… Thursday, November 20, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing

The insights lay the groundwork for earlier diagnosis and better treatment of the disease.

… Wednesday, February 3, 2021 Summary Both genes and environment are necessary to trigger pancreatic cancer development. A new study from the  Sloan Kettering Institute  at Memorial Sloan Kettering explains why. Like weeds sprouting from cracks in the pavement, cancer often forms in sites of tissue damage